CN101652062A - Toll样受体3(TLR3)的限制性激动剂 - Google Patents

Toll样受体3(TLR3)的限制性激动剂 Download PDF

Info

Publication number
CN101652062A
CN101652062A CN200880007263A CN200880007263A CN101652062A CN 101652062 A CN101652062 A CN 101652062A CN 200880007263 A CN200880007263 A CN 200880007263A CN 200880007263 A CN200880007263 A CN 200880007263A CN 101652062 A CN101652062 A CN 101652062A
Authority
CN
China
Prior art keywords
tlr3
virus
poly
subject
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880007263A
Other languages
English (en)
Chinese (zh)
Inventor
布赖恩·B·高恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Utah State University
Original Assignee
Utah State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Utah State University filed Critical Utah State University
Publication of CN101652062A publication Critical patent/CN101652062A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12211—Phlebovirus, e.g. Rift Valley fever virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200880007263A 2007-03-05 2008-03-05 Toll样受体3(TLR3)的限制性激动剂 Pending CN101652062A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90479207P 2007-03-05 2007-03-05
US60/904,792 2007-03-05

Publications (1)

Publication Number Publication Date
CN101652062A true CN101652062A (zh) 2010-02-17

Family

ID=39738981

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880007263A Pending CN101652062A (zh) 2007-03-05 2008-03-05 Toll样受体3(TLR3)的限制性激动剂

Country Status (11)

Country Link
US (1) US20100183638A1 (https=)
EP (1) EP2134172A4 (https=)
JP (1) JP2010520284A (https=)
KR (1) KR20090130019A (https=)
CN (1) CN101652062A (https=)
AU (1) AU2008223446B2 (https=)
BR (1) BRPI0808637A2 (https=)
CA (1) CA2680134A1 (https=)
NZ (1) NZ579433A (https=)
WO (1) WO2008109083A2 (https=)
ZA (1) ZA200905954B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102300997A (zh) * 2008-10-31 2011-12-28 森托科尔奥索生物科技公司 Toll样受体3拮抗剂

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067517A2 (en) 2005-12-07 2007-06-14 Hemispherx Biopharma Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants
WO2009102496A2 (en) * 2008-02-15 2009-08-20 Hemispherx Biopharma, Inc. Selective agonist of toll-like receptor 3
US8722874B2 (en) 2008-10-23 2014-05-13 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
AU2009308105B2 (en) * 2008-10-23 2016-07-07 Aim Immunotech Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US20100160413A1 (en) * 2008-10-23 2010-06-24 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US9090897B2 (en) * 2009-12-18 2015-07-28 Bavarian Nordic A/S Production of IFN-lambda by conventional dendritic cells
CN101780279B (zh) * 2009-12-22 2012-07-11 中山大学中山眼科中心 Toll-like receptor-3激动剂在制备促进伤口愈合的药物中的应用
EP2558069A1 (en) 2010-04-13 2013-02-20 Novartis AG Benzonapthyridine compositions and uses thereof
CA2802721C (en) * 2010-06-25 2015-08-18 Idera Pharmaceuticals, Inc. Novel agonists of toll-like receptor 3 and methods of their use
US10105305B2 (en) 2014-02-19 2018-10-23 The Johns Hopkins University Compositions and methods for promoting skin regeneration and hair growth
EP3321362A1 (en) 2016-11-10 2018-05-16 Centre Leon Berard Tlr3 agonist for use for inducing apoptosis in senescent cancer cells
EP3558350A1 (en) 2016-12-22 2019-10-30 Intervet International B.V. Eimeria vaccine with improved efficacy
CN112703011A (zh) 2018-08-06 2021-04-23 国家医疗保健研究所 用于治疗癌症的方法和组合物
WO2020232226A1 (en) 2019-05-16 2020-11-19 The Johns Hopkins University Compositions and methods for skin rejuvenation
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006054177A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer using tlr3 agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080726A (en) * 1985-08-12 2000-06-27 University Of Maryland Anti-viral and immuno stimulator polynucleotide duplex and use thereof
US5063209A (en) * 1985-08-26 1991-11-05 Hem Research, Inc. Modulation of aids virus-related events by double-stranded RNAs
IE72103B1 (en) * 1987-08-12 1997-03-12 Hem Res Inc Promotion of host defense by systemic dsRNA treatment
US5683986A (en) * 1987-08-12 1997-11-04 Hemispherx Biopharma Inc. Elaboration of host defense mediators into biological fluids by systemic dsRNA treatment
US5976800A (en) * 1996-06-28 1999-11-02 The Regents Of The University Of California Enhancement of cancer cell death
GB0119346D0 (en) * 2001-08-08 2001-10-03 Bioclones Proprietary Ltd Process for the maturation of dendritic cells
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006054177A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer using tlr3 agonists

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102300997A (zh) * 2008-10-31 2011-12-28 森托科尔奥索生物科技公司 Toll样受体3拮抗剂
CN102300997B (zh) * 2008-10-31 2016-01-20 森托科尔奥索生物科技公司 Toll样受体3拮抗剂

Also Published As

Publication number Publication date
EP2134172A2 (en) 2009-12-23
ZA200905954B (en) 2011-10-26
EP2134172A4 (en) 2011-06-01
BRPI0808637A2 (pt) 2014-08-05
KR20090130019A (ko) 2009-12-17
US20100183638A1 (en) 2010-07-22
WO2008109083A2 (en) 2008-09-12
CA2680134A1 (en) 2008-09-12
NZ579433A (en) 2012-05-25
AU2008223446B2 (en) 2012-02-02
JP2010520284A (ja) 2010-06-10
WO2008109083A3 (en) 2008-11-27
AU2008223446A1 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
CN101652062A (zh) Toll样受体3(TLR3)的限制性激动剂
Diebold Recognition of viral single-stranded RNA by Toll-like receptors
Mekonnen et al. SARS-CoV-2 subunit vaccine adjuvants and their signaling pathways
Liu et al. Interferon lambda in respiratory viral infection: immunomodulatory functions and antiviral effects in epithelium
Shah et al. Advances in antiviral therapies targeting toll-like receptors
Arico et al. Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?
US20100310600A1 (en) Selective agonist of toll-like receptor 3
US20100104533A1 (en) Early intervention of viral infection with immune activators
WO2018045760A1 (zh) 罗汉果醇在制备抗病毒药物中的应用
JP5209180B2 (ja) トリインフルエンザ感染の治療
CA2632516C (en) Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants
WO2015167616A1 (en) Guanosine as an immunepotentiator mediated through toll receptors
Logue et al. Treatment with cationic liposome–DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge
Gaajetaan et al. The type I interferon response during viral infections: a “SWOT” analysis
HK1136158A (en) Restrictive agonist of toll-like receptor 3 (tlr3)
US7550150B2 (en) Methods of treating or preventing a disease, disorder or condition associated with a viral infection
Deanasa et al. The potential of antisense oligonucleotides (ASO) through inhalation based on gold nanoparticle (AuNP) delivery system in inhibiting SARS-CoV-2 replication and transcription
KR101293363B1 (ko) 인터페론 수용체 유전자를 포함하는 조류독감 예방용 조성물
Nainwani et al. Macrophage Targeting for Therapy of HIV
US20230277650A1 (en) Use of a birnavirus for the treatment of a disease caused by varicella zoster virus (vzv)
AU2013206335B2 (en) dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
Mitchell TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly (I: C12U), but not Poly (I: C): differential recognition of synthetic dsRNA molecules
WO2021224646A1 (en) Method for the treatment of rna virus involved diseases
CN102526710A (zh) 一种治疗猪病毒病蛋白质组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1136158

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100217

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1136158

Country of ref document: HK